HSP32 and HSP90 Immunoexpression, in Relation to Kit Pattern, Grading, and Mitotic Count in Canine Cutaneous Mast Cell Tumors.

about

HSP32 and HSP90 Immunoexpression, in Relation to Kit Pattern, Grading, and Mitotic Count in Canine Cutaneous Mast Cell Tumors.

Item

http://www.wikidata.org/entity/Q39390655

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年学术文章

@wuu

2016年学术文章

@zh-cn

2016年学术文章

@zh-hans

2016年学术文章

@zh-my

2016年学术文章

@zh-sg

2016年學術文章

@yue

2016年學術文章

@zh

2016年學術文章

@zh-hant

name

HSP32 and HSP90 Immunoexpressi ...... ne Cutaneous Mast Cell Tumors.

@en

HSP32 and HSP90 Immunoexpressi ...... ne Cutaneous Mast Cell Tumors.

@nl

type

Item

label

HSP32 and HSP90 Immunoexpressi ...... ne Cutaneous Mast Cell Tumors.

@en

HSP32 and HSP90 Immunoexpressi ...... ne Cutaneous Mast Cell Tumors.

@nl

prefLabel

HSP32 and HSP90 Immunoexpressi ...... ne Cutaneous Mast Cell Tumors.

@en

HSP32 and HSP90 Immunoexpressi ...... ne Cutaneous Mast Cell Tumors.

@nl

P1476

HSP32 and HSP90 Immunoexpressi ...... ne Cutaneous Mast Cell Tumors.

@en

P2093

A Ciccarelli

http://www.w3.org/2001/XMLSchema#string

A Gasbarre

http://www.w3.org/2001/XMLSchema#string

L Bongiovanni

http://www.w3.org/2001/XMLSchema#string

L Della Salda

http://www.w3.org/2001/XMLSchema#string

M Massimini

http://www.w3.org/2001/XMLSchema#string

M Romanucci

http://www.w3.org/2001/XMLSchema#string

P2860

Phase I evaluation of STA-1474, a prodrug of the novel HSP90 inhibitor ganetespib, in dogs with spontaneous cancer

The novel HSP90 inhibitor STA-9090 exhibits activity against Kit-dependent and -independent malignant mast cell tumors

PLCγ1-PKCγ signaling-mediated Hsp90α plasma membrane translocation facilitates tumor metastasis.

Targeting of heat-shock protein 32/heme oxygenase-1 in canine mastocytoma cells is associated with reduced growth and induction of apoptosis.

Identification of heat shock protein 32 (Hsp32) as a novel survival factor and therapeutic target in neoplastic mast cells.

17-Allylamino-17-demethoxygeldanamycin (17-AAG) is effective in down-regulating mutated, constitutively activated KIT protein in human mast cells.

Expression of HSP90 in gastrointestinal stromal tumours and mesenchymal tumours.

P304

222-225

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/0300985816669405

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Daniela Malatesta

P577

2016-09-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27627984

http://www.w3.org/2001/XMLSchema#string

P921

mast cells